RESULTS	After median follow-up of 50 months ( IQR 32-67 ) , 69 breast cancers had been diagnosed in 3578 women in the tamoxifen group and 101 in 3566 in the placebo group ( risk reduction 32 % [ 95 % CI 8-50 ] ; p = 0.013 ) .\